Vibe analyzing my genome
The most interesting and useful result concerns drug metabolism; you can skip to that section here . What I did I had my genome sequenced by Nucleus Genomics. I downloaded various genome files from Nucleus and started a new Git repo within Cursor. I worked with the LLMs to make a plan, hoping to find insights that would help me prioritize treatments by better understanding my own conditions, e.g., identifying responsible pathways. Or rather, what Claude/ChatGPT did This is the dense description that will mean something specific to someone who knows anything about genetic analysis, and is otherwise supposed to seem impressive if you don't. In all seriousness, though, I think the LLMs do offer you more analysis than you can get by uploading your .vcf to a site, at the risk that they'll definitely lead you astray with interpretation unless you're careful. This project analyzed a 43x whole-genome sequence for a patient with bipolar, inflammatory symptoms, and extreme multi-drug sensitivity. The work included: data QC and coverage verification; pharmacogenomic star-allele calling via PharmCAT and Cyrius (CYP2D6); HLA class I typing via OptiType with tag SNP cross-validation; ClinVar and VEP functional annotation of a 76-gene candidate sweep; a genome-wide rare variant screen filtering 5 million variants down to 27 high-impact candidates; multi-trait polygenic risk scores for psychiatric and immune traits; two literature reviews synthesizing published genetic correlations (LDSC) and Mendelian randomization evidence for inflammation-psychiatry causal pathways; a critical adversarial review that checked all findings against population frequencies and ClinVar review
In recent years, the field of personalized medicine has gained significant traction, with individuals increasingly turning to genome sequencing to gain insights into their health. One such individual embarked on a unique journey by having their genome sequenced through Nucleus Genomics. This patient, suffering from bipolar disorder, inflammatory symptoms, and extreme multi-drug sensitivity, sought to leverage advanced genetic analysis to better understand their conditions and prioritize treatments.
The project began with the patient downloading various genome files from Nucleus Genomics and initiating a new Git repository within Cursor. With the help of large language models (LLMs), the team devised a comprehensive plan to explore the genomic data. The goal was to identify responsible pathways and gain insights that could aid in treatment prioritization.
The first step involved quality control (QC) and coverage verification of the 43x whole-genome sequence. This ensured that the data was accurate and complete, forming the foundation for subsequent analyses. Pharmacogenomic star-allele calling was conducted using PharmCAT and Cyrius, with a focus on the CYP2D6 gene, which plays a crucial role in drug metabolism.
HLA class I typing was performed using OptiType, with tag SNP cross-validation to confirm the accuracy of the results. This step was particularly important, as HLA genes are known to influence immune responses and drug reactions.
Next, the team conducted a functional annotation of a 76-gene candidate sweep using ClinVar and the Variant Effect Predictor (VEP). This allowed them to understand the potential impact of genetic variants on protein function and identify potential candidates for further study.
A genome-wide rare variant screen was then implemented, filtering down 5 million variants to just 27 high-impact candidates. This step was critical in narrowing down the list of potential genetic factors contributing to the patient's conditions.
Multi-trait polygenic risk scores for psychiatric and immune traits were calculated to assess the patient's predisposition to various health issues. These scores provided valuable information on the genetic basis of the patient's conditions and offered insights into potential preventive measures.
Two literature reviews were conducted, synthesizing published genetic correlations (LDSC) and Mendelian randomization evidence for inflammation-psychiatry causal pathways. These reviews aimed to establish a causal relationship between inflammation and psychiatric disorders, such as bipolar disorder, and to identify potential therapeutic targets.
A critical adversarial review was then performed, meticulously checking all findings against population frequencies and ClinVar review status. This step dismantled several overclaimed results, ensuring the accuracy and reliability of the analysis.
The rarity of the patient's multi-CYP profile was quantified through a joint probability calculation, revealing that it was approximately 1 in 23,000. This finding highlighted the unique genetic makeup of the patient and underscored the importance of personalized medicine.
A drug history cross-reference was conducted, mapping 23 medications to specific genotypes. This allowed the team to identify potential drug-gene interactions and understand why certain medications may have been more effective or caused adverse reactions.
Finally, a comprehensive drug contingency table was created, covering 75+ medications and their associated pathways. This table served as a valuable resource for healthcare providers, enabling them to make informed decisions about medication selection and dosing.
Throughout the project, the team relied heavily on LLMs to guide their analyses. While these models offered a more in-depth exploration of the genomic data than traditional methods, they also posed challenges in terms of interpretation. The patient emphasized the need for caution when interpreting results, as the models could potentially lead astray if not used judiciously.
In conclusion, this project exemplifies the potential of personalized medicine and the power of advanced genetic analysis. By leveraging cutting-edge technologies and collaborating with AI models, the patient was able to gain unprecedented insights into their health, paving the way for more effective treatments and a better understanding of complex conditions such as bipolar disorder and multi-drug sensitivity. As the field continues to evolve, it is likely that such projects will become increasingly common, offering individuals the opportunity to take a proactive role in their healthcare.
